GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (HKSE:01877) » Definitions » Forward PE Ratio

Shanghai Junshi Biosciences Co (HKSE:01877) Forward PE Ratio : 0.00 (As of May. 28, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Shanghai Junshi Biosciences Co Forward PE Ratio?

Shanghai Junshi Biosciences Co's Forward PE Ratio for today is 0.00.

Shanghai Junshi Biosciences Co's PE Ratio without NRI for today is 0.00.

Shanghai Junshi Biosciences Co's PE Ratio for today is 0.00.


Shanghai Junshi Biosciences Co Forward PE Ratio Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Forward PE Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Forward PE Ratio Chart

Shanghai Junshi Biosciences Co Annual Data
Trend 2020-12 2021-12
Forward PE Ratio
204.08 76.92

Shanghai Junshi Biosciences Co Quarterly Data
2020-12
Forward PE Ratio 204.08

Competitive Comparison of Shanghai Junshi Biosciences Co's Forward PE Ratio

For the Biotechnology subindustry, Shanghai Junshi Biosciences Co's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Shanghai Junshi Biosciences Co's Forward PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Shanghai Junshi Biosciences Co's Forward PE Ratio distribution charts can be found below:

* The bar in red indicates where Shanghai Junshi Biosciences Co's Forward PE Ratio falls into.



Shanghai Junshi Biosciences Co Forward PE Ratio Calculation

It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.


Shanghai Junshi Biosciences Co  (HKSE:01877) Forward PE Ratio Explanation

The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.

Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .


Shanghai Junshi Biosciences Co Forward PE Ratio Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Forward PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Shanghai Junshi Biosciences Co (HKSE:01877) Business Description

Traded in Other Exchanges
Address
Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN
Shanghai Junshi is a China-based biotechnology company that was founded in 2012 and listed on the Hong Kong Stock Exchange and STAR board of the Shanghai Stock Exchange in 2018 and 2020, respectively. It received approval for its first core asset at the end of 2018, a PD-1 inhibitor called Tuoyi, or toripalimab. It also successfully created etesevimab, one of the earliest neutralizing antibodies for COVID-19 treatment, which was out-licensed to Eli Lilly and obtained U.S. Food and Drug Administration approval in February 2021. It also has an adalimumab biosimilar approved in 2022 and is working on an oral COVID-19 treatment, VV116.
Executives
Gic (ventures) Pte. Ltd. 2201 Interest of corporation controlled by you
Gic Special Investments Private Limited 2102 Investment manager
Gic Private Limited 2201 Interest of corporation controlled by you
Highbury Investment Pte Ltd 2101 Beneficial owner
Jovial Champion Investments Limited 2201 Interest of corporation controlled by you
Gong Ruilin 2202 Interest of your spouse
Vistra Trust (singapore) Pte. Limited 2201 Interest of corporation controlled by you
Lvc Holdings Limited 2201 Interest of corporation controlled by you
Lvc Management Holdings Limited 2201 Interest of corporation controlled by you
Lvc Innovate Limited 2201 Interest of corporation controlled by you
Lin Lijun 2307 Founder of a discretionary trust who can infl
Lvc Renaissance Fund Lp 2101 Beneficial owner
Lvc Renaissance Limited 2201 Interest of corporation controlled by you
Loyal Valley Innovation Capital (hk) Limited 2201 Interest of corporation controlled by you
Lv Di Kong Gu Ji Tuan Gu Fen You Xian Gong Si 2201 Interest of corporation controlled by you

Shanghai Junshi Biosciences Co (HKSE:01877) Headlines

No Headlines